Xenetic Biosciences (XBIO) Asset Utilization Ratio (2012 - 2026)
Xenetic Biosciences' (XBIO) quarterly Asset Utilization Ratio came in at 0.39 in Q1 2026, down 3.66% YoY from 0.41 in Q1 2025, and down 11.53% on a QoQ basis from 0.44 in Q4 2025.
Xenetic Biosciences (XBIO) Asset Utilization Ratio (2012 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 14 years of Asset Utilization Ratio data on file, last reported at 0.39 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 3.66% year-over-year to 0.39 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.39 (down 3.66% YoY) and the FY2025 annual result came in at 0.39, up 36.52% from the prior year.
- Asset Utilization Ratio declined to 0.39 in Q1 2026, from 0.44 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.55 in Q3 2025 to a low of 0.07 in Q1 2022.
- A 5-year average of 0.26 and a median of 0.24 in 2024 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio surged 99.76% — and 2026, when it declined 3.66%.
- Tracing XBIO's Asset Utilization Ratio over 5 years: stood at 0.11 in 2022, then surged by 99.76% to 0.23 in 2023, then surged by 48.61% to 0.33 in 2024, then jumped by 32.48% to 0.44 in 2025, then slipped by 11.53% to 0.39 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.39 (Q1 2026), 0.44 (Q4 2025), and 0.55 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Xenetic Biosciences | 8.37 Mn | 1.90 Mn | - | 0.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.44 |
| Mar 31, 2026 | 0.39 |
| Dec 31, 2025 | 0.44 |
| Sep 30, 2025 | 0.55 |
| Jun 30, 2025 | 0.44 |
| Mar 31, 2025 | 0.41 |
| Dec 31, 2024 | 0.33 |
| Sep 30, 2024 | 0.30 |
| Jun 30, 2024 | 0.27 |
| Mar 31, 2024 | 0.24 |
| Dec 31, 2023 | 0.23 |
| Sep 30, 2023 | 0.19 |
| Jun 30, 2023 | 0.16 |
| Mar 31, 2023 | 0.14 |
| Dec 31, 2022 | 0.11 |
| Sep 30, 2022 | 0.10 |
| Jun 30, 2022 | 0.09 |
| Mar 31, 2022 | 0.07 |
| Dec 31, 2021 | 0.06 |
| Sep 30, 2021 | 0.06 |